Elevated alanine aminotransferase is strongly associated with incident metabolic syndrome: A meta-analysis of prospective studies

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Liu, Zhengtao ^a   Que, Shuping ^a,b   Ning, Huaijun ^b   Wang, Linlin ^a   Peng, Tao ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b Guangxi Women and Children Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; ENZYME ACTIVITY; HUMAN; INCIDENCE; METABOLIC SYNDROME X; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SYSTEMATIC REVIEW;

ADULT; AGED; ALANINE TRANSAMINASE; DATABASES, BIBLIOGRAPHIC; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS;

EID: 84891854434     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080596     Document Type: Article

References (68)

1. Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome. The Lancet 365: 1415-1428.
2. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, et al. (2010) The Metabolic Syndrome and Cardiovascular RiskA Systematic Review and Meta-Analysis. Journal of the American College of Cardiology 56: 1113-1132.
3. Aschner P (2010) Metabolic syndrome as a risk factor for diabetes. Expert Review of Cardiovascular Therapy 8: 407-412.
4. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, et al. (2007) Metabolic Syndrome and Risk of Incident Cardiovascular Events and DeathA Systematic Review and Meta-Analysis of Longitudinal Studies. Journal of the American College of Cardiology 49: 403-414.
5. Hui WS, Liu Z, Ho SC (2010) Metabolic syndrome and all-cause mortality: a meta-analysis of prospective cohort studies. European journal of epidemiology 25: 375-384.
6. James PT (2004) Obesity: the worldwide epidemic. Clinics in dermatology 22: 276-280.
7. Owen N, Healy GN, Matthews CE, Dunstan DW (2010) Too much sitting: the population-health science of sedentary behavior. Exercise and sport sciences reviews 38: 105.
8. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, et al. (2001) Nonalcoholic fatty liver disease a feature of the metabolic syndrome. Diabetes 50: 1844-1850.
9. Reid AE (2001) Nonalcoholic steatohepatitis. Gastroenterology 121: 710-723.
10. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, et al. (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37: 917-923.
11. Nakanishi N, Suzuki K, Tatara K (2004) Serum γ-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care 27: 1427-1432.
12. Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB, et al. (2005) Liver Markers and Development of the Metabolic Syndrome The Insulin Resistance Atherosclerosis Study. Diabetes 54: 3140-3147.
13. André P, Balkau B, Vol S, Charles MA, Eschwège E (2007) γ-Glutamyltransferase Activity and Development of the Metabolic Syndrome (International Diabetes Federation Definition) in Middle-Aged Men and Women Data From the Epidemiological Study on the Insulin Resistance Syndrome (DESIR) cohort. Diabetes Care 30: 2355-2361.
14. Schindhelm R, Dekker J, Nijpels G, Stehouwer C, Bouter L, et al. (2007) Alanine aminotransferase and the 6-year risk of the metabolic syndrome in Caucasian men and women: the Hoorn Study. Diabetic medicine 24: 430-435.
15. Goessling W, Massaro JM, Vasan RS, D'Agostino Sr RB, Ellison RC, et al. (2008) Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 135: 1935.
16. Jo S-K, Lee W-Y, Rhee E-J, Won J-C, Jung C-H, et al. (2009) Serum γ-glutamyl transferase activity predicts future development of metabolic syndrome defined by 2 different criteria. Clinica Chimica Acta 403: 234-240.
17. XU Y, XU M, HUANG Y, NING G (2011) Cross: 234-240. and longitudinal association of serum alanine aminotransaminase and γ-glutamyl transferase act metabolic syndrome in middleassociand elderly Chinese people. Journal of Diabetes 3: 38-47.
18. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of internal medicine 151: 264-269.
19. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Meta-analysis of observational studies in epidemiology. JAMA: the journal of the American Medical Association 283: 2008-2012.
20. Cohen J (1968) Weighted kappa: Nominal scale agreement provision for scaled disagreement or partial credit. Psychological bulletin 70: 213.
21. Wells G, Shea B, O'Connell D, Peterson P, Welch V, et al. (2011) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute.
22. Harris R, Bradburn M, Deeks J, Harbord R, Altman D, et al. (2008) Metan: fixed-and random-effects meta-analysis. Stata Journal 8: 3.
23. Greenland S, Longnecker MP (1992) Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. American Journal of Epidemiology 135: 1301-1309.
24. Orsini N, Bellocco R, Greenland S (2006) Generalized least squares for trend estimation of summarized dose-response data. Stata Journal 6: 40-57.
25. Berlin JA, Longnecker MP, Greenland S (1993) Meta-analysis of epidemiologic dose-response data. Epidemiology 4: 218-228.
26. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ: British Medical Journal 327: 557.
27. Steichen T (2001) METANINF: Stata module to evaluate influence of a single study in meta-analysis estimation. Statistical Software Components.
28. Sterne JA, Egger M (2001) Funnel plots for detecting bias in meta-analysis-Guidelines on choice of axis. Journal of clinical epidemiology 54: 1046-1055.
29. Detection EPO (2001) EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Jama 285: 2486-2497.
30. Alberti K, Zimmet P, Shaw J (2005) The metabolic syndrome-a new worldwide definition. Lancet 366: 1059.
31. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, et al. (2005) Diagnosis and management of the metabolic syndrome an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112: 2735-2752.
32. Alberti K, Zimmet P (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic medicine 15: 539-553.
33. Ioannou GN, Weiss NS, Boyko EJ, Mozaffarian D, Lee SP (2006) Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology 43: 1145-1151.
34. Pratt DS, Kaplan MM (2000) Evaluation of abnormal liver-enzyme results in asymptomatic patients. New England Journal of Medicine 342: 1266-1271.
35. Clark JM, Brancati FL, Diehl AM (2003) The prevalence and etiology of elevated aminotransferase levels in the United States. The American journal of gastroenterology 98: 960-967.
36. Bellentani S, Saccoccio G, Costa G, Tiribelli C, Manenti F, et al. (1997) Drinking habits as cofactors of risk for alcohol induced liver damage. Gut 41: 845-850.
37. Ruhl CE, Everhart JE (2003) Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. GASTROENTEROLOGY-BALTIMORE THEN PHILADELPHIA- 124: 71-79.
38. Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047-1053.
39. Liangpunsakul S, Chalasani N (2005) Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III). The American journal of the medical sciences 329: 111-116.
40. Chu CM, Liaw YF, Sheen I, Lin DY, Huang MJ (1983) Sex difference in chronic hepatitis B virus infection: an appraisal based on the status of hepatitis B e antigen and antibody. Hepatology 3: 947-950.
41. Roudot-Thoraval F, Bastie A, Pawlotsky J, Dhumeaux D (1997) Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: A French survey of 6,664 patients. Hepatology 26: 485-490.
42. Chen CJ, Wang LY, Yu MW (2000) Epidemiology of hepatitis B virus infection in the Asia-Pacific region. Journal of gastroenterology and hepatology 15: E3-E6.
43. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, et al. (2001) Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 34: 809-816.
44. Chen SL, Morgan TR (2006) The natural history of hepatitis C virus (HCV) infection. International journal of medical sciences 3: 47.
45. Kim CH, YOUNOSSI ZM (2008) Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleveland Clinic Journal of Medicine 75: 721-728.
46. Liu Z, Hu Y, Yang X, Tan A, Gao Y, et al. (2012) Combinative analysis of factors influence serum alanine aminotransferase activity in adult male population from southern China. Clinical Biochemistry.
47. Kim W, Flamm SL, Di Bisceglie AM, Bodenheimer HC (2008) Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 47: 1363-1370.
48. Pendino GM, Mariano A, Surace P, Caserta CA, Fiorillo MT, et al. (2005) Prevalence and etiology of altered liver tests: A population-based survey in a Mediterranean town. Hepatology 41: 1151-1159.
49. Chen CH, Huang MH, Yang JC, Nien CK, Yang CC, et al. (2007) Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan. Journal of gastroenterology and hepatology 22: 1482-1489.
50. Boppidi H, Daram SR (2008) Nonalcoholic fatty liver disease: hepatic manifestation of obesity and the metabolic syndrome. Postgraduate medicine 120: E01.
51. Liu CF, Zhou WN, Fang NY (2012) Gammaic fatty liver disease: hepatic manifestation of obesity and the metabolic syndrome. Postgraduate medicine 120: E01.
52. on in journal of clinical practice 66: 692-698.
53. Browning JD, Szczepaniak LS, Dobbins R, Horton JD, Cohen JC, et al. (2004) Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40: 1387-1395.
54. Eguchi Y, Eguchi T, Mizuta T, Ide Y, Yasutake T, et al. (2006) Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease. Journal of gastroenterology 41: 462-469.
55. Sattar N, McConnachie A, Ford I, Gaw A, Cleland SJ, et al. (2007) Serial Metabolic Measurements and Conversion to Type 2 Diabetes in the West of Scotland Coronary Prevention Study Specific Elevations in Alanine Aminotransferase and Triglycerides Suggest Hepatic Fat Accumulation as a Potential Contributing Factor. Diabetes 56: 984-991.
56. Lorenzo C, Hanley A, Rewers M, Haffner S (2013) The association of alanine aminotransferase within the normal and mildly elevated range with lipoproteins and apolipoproteins: the Insulin Resistance Atherosclerosis Study. Diabetologia: 1-12.
57. Den Boer M, Voshol P, Kuipers F, Havekes L, Romijn J (2004) Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. Arteriosclerosis, thrombosis, and vascular biology 24: 644-649.
58. Seppälä-Lindroos A, Vehkavaara S, Häkkinen A-M, Goto T, Westerbacka J, et al. (2002) Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. Journal of Clinical Endocrinology & Metabolism 87: 3023-3028.
59. Vozarova B, Stefan N, Lindsay RS, Saremi A, Pratley RE, et al. (2002) High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 51: 1889-1895.
60. Regitz-Zagrosek V, Lehmkuhl E, Weickert MO (2006) Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clinical Research in Cardiology 95: 136-147.
61. Travers SH, Jeffers BW, Eckel RH (2002) Insulin resistance during puberty and future fat accumulation. Journal of Clinical Endocrinology & Metabolism 87: 3814-3818.
62. Murphy MJ, Metcalf BS, Voss LD, Jeffery AN, Kirkby J, et al. (2004) Girls at five are intrinsically more insulin resistant than boys: the programming hypotheses revisited-The EarlyBird Study (EarlyBird 6). Pediatrics 113: 82-86.
63. Moran A, Jacobs DR, Steinberger J, Hong C-P, Prineas R, et al. (1999) Insulin resistance during puberty: results from clamp studies in 357 children. Diabetes 48: 2039-2044.
64. Ehm MG, Karnoub MC, Sakul H, Gottschalk K, Holt DC, et al. (2000) Genomewide search for type 2 diabetes susceptibility genes in four American populations. The American Journal of Human Genetics 66: 1871-1881.
65. Olynyk JK, Knuiman MW, Divitini ML, Davis TM, Beilby J, et al. (2009) Serum alanine aminotransferase, metabolic syndrome, and cardiovascular disease in an Australian population. The American journal of gastroenterology 104: 1715-1722.
66. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH (2003) Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Archives of pediatrics & adolescent medicine 157: 821.
67. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, et al. (2004) Obesity and the metabolic syndrome in children and adolescents. New England Journal of Medicine 350: 2362-2374.
68. Cheng S, Rhee EP, Larson MG, Lewis GD, McCabe EL, et al. (2012) Metabolite Profiling Identifies Pathways Associated With Metabolic Risk in HumansClinical Perspective. Circulation 125: 2222-223.